Broad Spectrum Antiangiogenic Treatment for Ocular Neovascular Diseases

DSpace/Manakin Repository

Broad Spectrum Antiangiogenic Treatment for Ocular Neovascular Diseases

Citable link to this page


Title: Broad Spectrum Antiangiogenic Treatment for Ocular Neovascular Diseases
Author: Benny, Ofra; Nakai, Kei; Bazinet, Lauren; Nakao, Shintaro; Hafezi-Moghadam, Ali; Pakneshan, Pouya; Yoshimura, Takeru; Akula, James Daniel; Panigrahy, Dipak; D'Amato, Robert John

Note: Order does not necessarily reflect citation order of authors.

Citation: Benny, Ofra, Kei Nakai, Takeru Yoshimura, Lauren Bazinet, James D. Akula, Shintaro Nakao, Ali Hafezi-Moghadam, Dipak Panigrahy, Pouya Pakneshan, and Robert J. D'Amato. 2010. Broad spectrum antiangiogenic treatment for ocular neovascular diseases. PLoS ONE 5(9): e12515.
Full Text & Related Files:
Abstract: Pathological neovascularization is a hallmark of late stage neovascular (wet) age-related macular degeneration (AMD) and the leading cause of blindness in people over the age of 50 in the western world. The treatments focus on suppression of choroidal neovascularization (CNV), while current approved therapies are limited to inhibiting vascular endothelial growth factor (VEGF) exclusively. However, this treatment does not address the underlying cause of AMD, and the loss of VEGF's neuroprotective can be a potential side effect. Therapy which targets the key processes in AMD, the pathological neovascularization, vessel leakage and inflammation could bring a major shift in the approach to disease treatment and prevention. In this study we have demonstrated the efficacy of such broad spectrum antiangiogenic therapy on mouse model of AMD.Methods and Findings Lodamin, a polymeric formulation of TNP-470, is a potent broad-spectrum antiangiogenic drug. Lodamin significantly reduced key processes involved in AMD progression as demonstrated in mice and rats. Its suppressive effects on angiogenesis, vascular leakage and inflammation were studied in a wide array of assays including; a Matrigel, delayed-type hypersensitivity (DTH), Miles assay, laser-induced CNV and corneal micropocket assay. Lodamin significantly suppressed the secretion of various pro-inflammatory cytokines in the CNV lesion including monocyte chemotactic protein-1 (MCP-1/Ccl2). Importantly, Lodamin was found to regress established CNV lesions, unlike soluble fms-like tyrosine kinase-1 (sFlk-1). The drug was found to be safe in mice and have little toxicity as demonstrated by electroretinography (ERG) assessing retinal and by histology. Conclusions: Lodamin, a polymer formulation of TNP-470, was identified as a first in its class, broad-spectrum antiangiogenic drug that can be administered orally or locally to treat corneal and retinal neovascularization. Several unique properties make Lodamin especially beneficial for ophthalmic use. Our results support the concept that broad spectrum antiangiogenic drugs are promising agents for AMD treatment and prevention.
Published Version: doi:10.1371/journal.pone.0012515
Other Sources:
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at
Citable link to this page:
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search